Sign in
Active, not recruitingPhase 3

Effect of Simvastatin on the Prognosis of Primary Primary Sclerosing Cholangitis (PSC)

Key facts

Who runs it
Annika Bergquist
Where
Sweden12 sites in 1 countryChoose a country to see its sites
Trial code
Status
Active, not recruiting
Phase
Phase 3
People taking part
571 people enrolled
Started
1 Oct 2020
Expected to end
31 Mar 2030
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Simvastatin 40mg
  • Placebo oral tablet
Record updated
5 September 2025

Who can take part

Age
18 years to 75 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • PSC verified by cholangiography or liver biopsy, with or without irritable bowel disease (IBD)
  • Men and women between ≥18 years and ≤75 years
  • Written informed consent
  • A magnetic resonance imaging (MRI) or Magnetic resonance cholangiopancreatography (MRCP) performed within 4 months prior to randomization
  • Colonoscopy performed within 24 months prior to randomization, if known IBD
  • For women of childbearing potential efficient contraceptive

Who cannot take part

  • Subjects on waiting list for transplantation
  • Previous variceal bleeding
  • Previous hepatobiliary malignancy
  • Intake of any type of statins within 3 months prior to randmization
  • Transplanted subjects
  • Subjects with secondary sclerosing cholangitis
  • Known intolerance to simvastatin
  • Pregnancy or breastfeeding

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This is a randomized, double-blind, placebo controlled multicenter study.

Read full original descriptionShow less

A total of 700 patients will be included. After an updated powercalculation 560 was condidered enough

The study will include patients with primary sclerosing cholangitis (PSC) for daily intake of 40 mg simvastatin/placebo for 5 years. The aim is to study effect of prognosis of PSC by long term intake of simvastatin. Outcome measures are death, liver transplantation, cholangiocarcinoma or bleeding from esophageal varices.

Subjects will be randomized (1:1) between Simvastatin and placebo.

The 2 groups in the trial

  • SimvastatinTreatment being tested

    Simvastatin 40 mg administered orally daily for 5 years.

    Treatment: Simvastatin 40mg

  • PlaceboPlacebo, for comparison

    Placebo for Simvastatin 40 mg administered orally daily for 5 years.

    Treatment: Placebo oral tablet

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Effect of Simvastatin on the Prognosis of Primary Sclerosing Cholangitis (PSC); A Randomized, Double-blind, Placebo Controlled Multicenter Study
Publications
Record updated
5 September 2025